Background

       Diabetes mellitus, herein diabetes, is a major global health issue, affecting an estimated 382 million people worldwide. The global prevalence of diabetes is rising, and by 2035 approximately 592 million people will be affected [1]. Poorly controlled diabetes can predispose patients to diabetic foot ulcers (DFU s). It has been estimated that 15% of diabetics will develop a DFU in their lifetime [2]. Te costs associated with DFU care are substantial. In 2014–2015 the annual cost of care for diabetic foot in England was estimated to be around £1 billion [3].

       The aetiology of DFUs typically reflects trauma superimposed upon peripheral neuropathy and ischaemia. Such diabetic foot ulcers commonly become sources of intransigent infection, whereupon they may be termed diabetic foot infections (DFIs). Although initially superficial, DFIs can become complicated by osteomyelitis [4]. Management of DFIs is limited to wound care, antibiotics and amputation [5]. These infections can be difficult to treat and, despite the administration of multiple rounds of antibiotics, prospects of clinical resolution of infection can still be poor and repeated courses of antibiotics risks selecting for antimicrobial resistance. A recent study in the United Kingdom found that one year after diagnosis, 55% of DFI patients were still infected and almost 15% had undergone amputation [6]. Te treatment of DFIs therefore represents a significant clinical challenge.

        An understanding of the microbiology of DFIs is key to tackling this clinical challenge. The microbiology of DFIs infections has been thoroughly investigated by prospective and retrospective studies. A diverse range of pathogens may be isolated from DFIs, reflecting the chronic, open, nature and anatomical location of these infections [7]. DFIs can be either mono- or polymicrobial, with polymicrobial being common among chronic infections that have undergone previous antibiotic treatment [8]. Gram positive cocci, particularly Staphylococci, are frequently isolated [9]. However, Gram negative organisms including Enterococcus faecalis, Enterobacter cloacae and Proteus mirabilis have also been observed at notable frequencies [10]. Deeper DFIs have been shown by some studies to be associated with the presence of anaerobic organisms [11]. Organisms with antimicrobial resistance are commonly found in DFIs, potentially reflecting the extent of patient interaction with healthcare environments or because of exposure to repeated courses of antibiotics [12]. Moreover, bacteria frequently form biofilms that resist immune clearance and promote antimicrobial resistance [13]; in one study 78.2% of chronic wounds showed evidence of biofilm production [14].

         A greater understanding of the microbiology of DFIs is important to help inform antimicrobial therapy and direct the development of novel therapeutics. While there have been many small or moderate scale investigations, to date no meta-analysis has sought to examine the global prevalence of the different microbes identified. Therefore, the aim of this meta-analysis was to use diagnostic studies of any design which reported data for 10 or more DFI culture results to investigate the prevalence of bacteria isolated from DFIs.

Methods

Search strategy

        Four electronic databases were searched for articles published from 1980 up to and including 2019: EMBASE (1980–2019), Ovid MEDLINE® Epub Ahead of Print, In-Process & Other Non-Indexed Citations,Ovid MEDLINE ® Daily, Ovid MEDLINE and Versions® (1946–2019), Web of Science and BIOSIS Citation Index (1926–2019). Te Web of Science Core Collection Citation Indexes searched were: Science Citation Index Expanded (1900–2019), Book Citation Index-Science (2005–2019) and the Emerging Sources Citation Index (2015–2019). Te search was performed using the following terms: (diabe* adj2 [foot or toe]) AND (osteo* OR ulcer* OR lesion* OR infect*) AND (culture* OR microbio* OR bacteria* OR isolate* OR pathogen$ OR sequenc* OR swab*). In Ovid these terms were followed by the suffix ‘.mp.’ and they were searched as topics in Web of Science. A study protocol was not published prior to this study.

Study selection criteria

        All studies underwent title and abstract screening, eligible studies met the following criteria: (1) the patients had been diagnosed with diabetes mellitus and a diabetic foot infection; (2) primary microbiological culture results were collected from foot swabs or biopsies; (3) it was clearly stated or could be reasonably inferred that one clinical sample was obtained per patient, data presented as percentages were excluded if they could not confidently be converted into raw data; (4) microbiological prevalence data had to be presented in full; (5) the study was published in the English language; (6) to minimize selection bias from individual case reports or short case series, studies had to contain data for 10 or more patients. There were no limitations on study type or location. For studies which presented the results of both superficial and deep sampling methods for all patients only the data from the deep sampling method was included. Where there was no mention of culture negative clinical samples there were assumed to be none, unless otherwise reasonably implied. Studies were excluded if they contained any discrepancy between summary values and raw data. Where studies provided antibiotic sensitivity data but did not explicitly report the frequency of MRSA, we used evidence of S. aureus resistance to methicillin or oxacillin to deduce the frequency of MRSA. Te term ‘diphtheroid’ is synonymous with Corynebacterium and data from both was combined under the latter heading.

       Eligible studies were accessed in full to ensure they fulfilled the inclusion criteria and provided sufficient data for the meta-analysis. Studies which could not be accessed in full, including presentation abstracts and articles behind paywalls, were excluded. A few studies required additional interpretation. One study referred to ‘Staphylococcus: COP’, interpreted as coagulase-positive S. aureus (15). Another study referred to ‘ Streptococcus aureus’, despite showing Streptococcus as a separate column; this was also assumed to represent S. aureus [16]. A further study referred to ‘central nervous system’, interpreted as CNS or coagulase-negative Staphylococci [17].

       Title and abstract and full-text screening were performed independently by the authors (SB/KM, JDJ), with discrepancies resolved by agreement or, where necessary, a third author (HJS). Deduplication was performed using Endnote (version X8.0.1). This review was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [18], and a PRISMA checklist completed (see Additional file 1).

Data extraction and critical appraisal

       The following information was extracted from each study into a spreadsheet: publication year; author(s); short citation; title; study design; study date(s); country; national income classification; whether anaerobes were tested for; whether patients on antibiotics were excluded; the number of patients cultured, samples, positive samples, samples without growth, samples with polymicrobial culture, samples with monomicrobial culture; the total number of microorganisms isolated; the frequency of bacterial genera or species isolated. Prevalence data were collected per bacterial genera, with the exceptions of  S. aureus and E. coli which were consistently reported species. National income classification was based on Gross National Income classification from Te World Bank [19]. Data extraction was performed independently by the authors (SB/KM, JDJ), with discrepancies resolved by agreement or, where necessary, a third author (HJS). All eligible studies were critically assessed using a modified Joanna Briggs Institute checklist for prevalence studies [20]. Critical appraisal was performed independently by two authors (SB, JDJ), with discrepancies resolved by a third author (HS). Te influence of potential publication bias is addressed in the discussion.

Statistical analysis

       Random-effects meta-analyses were used throughout to calculate the pooled prevalence of the bacterial species identified with 95% confidence intervals (95% CIs). Study heterogeneity was assessed by the I2 statistic, reported with 95% CIs, and interpreted as low (≤25%), moderate (25–75%) or high (≥75%) [21]. All meta-analyses were carried out using MedCalc statistical software, version 19.8 (MedCalc Software, Ostend, Belgium). Te association between the study dates and bacterial prevalence was assessed by linear regression, using Excel (version 2104; Microsoft Corporation, Seattle, United States). Te significance of proportions was compared using the MedCalc N-1 Chi-squared calculator [22].

Results

Study selection and characteristics

      Systematic searching of four databases yielded 8743 articles. Deduplication removed 3137 and two aberrant entries were removed, one was a corrupt entry and one published outside the search date range. Te titles and abstracts of the remaining 5604 were screened against the selection criteria. A further 12 relevant articles were identified from related meta-analyses and also screened [23,24,25]. Title and abstract screening identified 410 eligible articles, 297 of which were subsequently excluded after full-text screening. Articles were excluded because they were not available in full (n=142), unclear or did not present a full analysis of the data (n=94), did not contain relevant data (n=46), were not available in English (n =12) or were not primary literature (n=4). Te study selection process is shown in Fig. 1. A total of 112 studies were eligible for inclusion (see Additional file 2). These comprised 76 prospective studies, 33 retrospective studies and three clinical trials. While critical appraisal of eligible studies highlighted shortcomings in reporting it did not reveal further grounds to exclude any studies (see Additional file 3).

       Most of the 112 studies (n=84) of the studies were published between 2011 and 2019, 25 took place between 2000 and 2010 and three were published before the year 2000, the earliest in 1984. Te most frequent study locations were India (n=32), Turkey (n=8), China (n=7) and France (n=7). One study did not report the study location. Where reported, there were 42 study populations from high-income countries (HICs), 27 from upper middle-income countries (UMICs), 42 from lower-middle income countries (LMICs) and none from low-income countries. Patients that had recently been on antibiotics were excluded in 23 studies. Almost half (n=55) of the studies tested for both anaerobic and aerobic bacterial species, while the remaining 57 studies tested only for aerobic bacteria.

       The 112 studies contained microbiological prevalence data for 16,159 patients, of which 14,445 (89.4%) were positive for microbial growth. A total of 22,198 microbial isolates were obtained from these positive cultures; 1.54 isolates per culture. These were overwhelmingly bacterial, although 258 fungal isolates and one archaea were identified. Te genus of most bacterial isolates was clearly reported, except for 231 unspecified Gram negative isolates, 127 unspecified Gram positive isolates, 416 members of the Enterobacteriaceae family and 141 unspecified isolates. Complete data about the frequency of negative culture, polymicrobial and monomicrobial results was available from 75 studies, representing 9737 patients. Of these, 8568 (88.0%) were culture positive, with 41.1% yielding monomicrobial growth and 58.9% yielding polymicrobial growth.

A diverse range of microbial species is found in diabetic

foot infections

       The 112 datasets were used to determine the frequency of the organisms identified in DFIs. First, the studies were divided into two groups, those that tested for only aerobic isolates (n=57) and those that tested for both aerobic and anaerobic isolates (n =55).

       The 57 studies that tested for only aerobic growth represented 6736 clinical samples, of which 5945 (88.3%) were culture positive, yielding 8418 microbial isolates. The frequency of bacterial genera detected on five or more occasions is shown in Fig.  2. The three most frequently identified organisms were Staphylococcus aureus, Pseudomonas spp.  and E. coli. To obtain a weighted average, meta-analyses were performed to investigate the pooled prevalence of each bacterial genus. These prevalence data are shown in the forest plot in Fig. 3. These meta-analyses show that the most frequently isolated aerobic organisms were S. aureus (23.4%; 95% CI 19.4–27.7%; I2 =95.1% [94.3–95.8%]), Pseudomonas spp. (11.1%; 95% CI 9.4–13.0%; I2= 85.0% [77.2–85.7%]), coli (11.5%; 95% CI 9.6–13.6%;I2 =87.5% [84.6–89.9%])，Proteus spp. (8.3%; 95% CI 6.5–10.3%; I2=89.7% [87.4–91.6%]), Klebsiella spp. (6.9%; 95% CI 5.3–8.7%; I2=89.6% [87.3–91.4%]) and Enterococcus spp. (5.4%; 95% CI 4.0–7.0%; I2=88.8% [84.7–90.9%]).

       The 55 studies that tested for aerobic and anaerobic growth represented 9423 clinical samples, of which 8500 (90.2%) were culture positive, yielding 13,763 microbial isolates. Te frequency of bacterial genera detected on five or more occasions is shown in Fig.  4. Te three most frequently identified organisms were Staphylococcus aureus, Enterococcus spp. and Pseudomonas spp. As before, meta-analyses were performed to investigate the pooled prevalence of each bacterial genus. These prevalence data are shown in the forest plot in Fig.  5. These meta-analyses show that the most frequently isolated aerobic organisms are S. aureus (21.3%; 95% CI 18.9–23.7%; I2=91.0% [89.0–92.3%]), Pseudomonas spp. (9.9%; 95% CI 8.2–11.7%; I2= 90.8% [88.9–92.5%]), E. coli (7.9%; 95% CI 6.0–9.9%; I2=94.3% [93.3–95.2%]), Enterococcus spp. (7.1%; 95% CI 5.7–8.6%; I2 =90.3% [88.1–92.1%]), Proteus spp. (6.1%; 95% CI 4.6–7.8%; I2= 93.1% [91.7– 94.2%]), coagulase-negative Staphylococci (5.8%; 95% CI 4.2–7.7%; I2=94.7% [93.8–95.5%]) and Streptococcus spp. (5.2%; 95% CI 3.8–6.8%; I2 =93.2% [91.9–94.3%]). Anaerobic organisms were not notably prevalent, with only Bacteroides spp. (2.0%; 95% CI 1.3–2.9%; I2=90.5% [88.4–92.2%]) and Peptostreptococcus spp. (1.4%; 95% CI 0.8–2.1%; I2=88.8% [86.2–90.9%]) occurring at a prevalence of greater than 1%.

The prevalence of MRSA among DFIs

       Diabetic patients are thought to have a higher chance of being colonized or infected by MRSA than non-diabetic patients [26, 27]. S. aureus isolates were detected in 109 of the 112 studies. A meta-analysis was used to investigate the proportion of S. aureus isolates that were reported as MRSA. Te 109 studies included in this analysis represented 15,670 clinical samples, among which 5073 S. aureus isolates were obtained. The proportion of MRSA among these isolates was 18.0% (95% CI 13.8–22.6%; I2=93.8% [93.0–94.5%]). There was no correlation between year of publication and the prevalence of MRSA among S. aureus isolates (R2=0.0024; data not shown).

Microbial prevalence correlates with gross national income

       The 112 datasets included in this study were drawn from a wide range of countries, representing varying levels of healthcare provision and sanitation. It has been suggested that DFIs from less developed countries more often contain Gram negative organisms, with Gram positive organisms predominating among DFIs in more developed nations [28]. We therefore investigated whether the prevalence of aerobic Gram negative and Gram positive bacteria found in DFIs varied by Gross.

      National Income (GNI). The 57 studies which used only aerobic culture were divided into two groups. The first group contained 13 studies from high-income countries (HICs), representing 1900 clinical samples from which 2317 isolates were obtained. Te second group contained 43 studies from upper-middle and lower-middle income countries (U/LMICs), representing 4786 clinical samples from which 6051 isolates were obtained. There was one further study, the location of which was not reported.

      The proportion of Gram positive and negative isolates was compared between studies from HICs and U/LMICs, excluding fungal, archaeal and unspecified isolates. The 13 studies from HICs reported 2273 isolates that were classified by Gram staining, of which 62.4% were Gram positive and 37.6% Gram negative. Te 43 studies from U/LMICs reported 5970 isolates that were classified by Gram staining, of which 40.4% were Gram positive and 59.6% Gram negative. Te 22.0% (95% CI 19.6–24.3%) difference between the proportion of Gram positive and negative isolates between U/LMICs and HICs was signifcant (P<0.0001).

       The data from the above meta-analyses of the prevalence of bacterial genera were used to select the most commonly occurring Gram positive and Gram negative genera. Te meta-analytic prevalence of these genera was calculated using the data from studies undertaken in HICs and U/LMICs. These data are shown in Fig.  6. The prevalence of Streptococcal species was significantly greater among HICs. The prevalence of Enterococcus spp. and S. aureus was also higher among HICs, but not significantly so. Among the Gram negative genera, Klebsiella spp. and E. coli were significantly more common among DFIs in U/LMICs than HICs. Proteus spp. and Pseudomonas spp. were also more prevalent among U/ LMICs, but not significantly so. Finally, we compared the prevalence of MRSA reported in studies from HICs and U/LMICs. Te 13 studies from HICs reported S. aureus isolates, with a total of 624, among which the prevalence of MRSA was 22.5% (95% CI 12.1–35.1%; I2=91.1% [86.6–94.1%]). Forty of the 43 studies from U/LMICs reported S. aureus isolates, with a total of 1314, among which the prevalence of MRSA was 19.2% (95% CI 11.5– 28.2%; I2=93.4% [91.8–94.6%]). Overlapping 95% confidence intervals showed that the difference between the proportion of MRSA identified in studies from HICs and U/LMICs was not significant.

 

Discussion

       The microbiology of diabetic foot infection has been well characterised using classical microbiological and molecular techniques. This meta-analysis examined culture results from eligible studies to provide an overview of the microbiology of diabetic foot infections. A diverse range of bacterial genera were identified. A perennial challenge is the delineation of which microbe(s) are pathogenic and which are incidental. Molecular investigations have shown that diabetic foot infections often contain an array of organisms [29, 30]. Te analysis of the microbiology of diabetic foot infections is further complicated by the potential for contamination of clinical samples by commensal bacteria. A high frequency of coagulase-negative Staphylococci was observed in this meta-analysis, which likely reflects a combination of sample contamination and genuine pathology caused by the introduction of commensals into tissues. Nonetheless, this meta-analysis clearly identified a high prevalence of bacterial species/genera classically associated with diabetic foot infection,e.g. S. aureus. Te prevalence of MRSA identified by this meta-analysis (18.0%) matches closely with previous estimates [12, 31]. We acknowledge that there can be notable local variation in the microbiology of diabetic foot infections, and local microbiological knowledge must drive day-to-day clinical practice. However, macroscopic data such as this will be useful for prioritising targets for novel therapeutic interventions, for example bacteriophage therapy [32].

        We used these data to investigate a previous assertion in the literature that Gram positive organisms might predominate in diabetic foot infections from more developed nations [28]. These data supported this correlation, with a significantly greater prevalence of Gram positive isolates among HICs and Gram negative isolates among U/LMICs. Tis held, although not always significantly, in general and with examination of the most commonly occurring Gram positive (S. aureus, Streptococcus spp., Enterococcus spp.) and Gram negative organisms (Pseudomonas spp., E. coli, Klebsiella spp., Proteus spp.). This may refect differences in sanitation, hygiene or use of footwear [28, 33].

        These data are limited by several factors. Firstly, to calculate the meta-analytic prevalence of each bacterial genera or species it was necessary to assume that all included studies had the same chance of detecting any given genera or species. In practice, this will depend on the skill, equipment and practices of the individual clinical microbiology laboratories. This will create underestimations of prevalence for bacterial genera or species that are uncommon or difficult to detect. Secondly, the majority of studies were conducted in U/LMICs (n=43/112), notably India (n =21/112). This may reflect negative publication bias among HICs, where such data may not be considered to be of sufficient interest for publication.This may create an over-representation of the prevalence of Gram negative organisms. Thirdly, the heterogeneity (I2 ) in the meta-analytic data was generally high, likely reflecting the multiple factors that would create different local microbiological profiles (e.g. patient demographics, circulating bacterial strains, local hygiene). Fourthly, this study may also be limited by not being preregistered. Registration of reviews is a non-essential recommendation designed to encourage transparency, improve quality and reduce duplication. Preregistration of reviews that are undertaken during student training or that are never completed is not recommended [34]. This study was conceived as a student project, many of which are not published, and the authors therefore decided it was inappropriate to register retrospectively. However, the authors are not aware of any similar studies underway and complied with the PRISMA statement throughout. Despite these limitations, these data provide a generally robust overview of the bacterial most frequently identified in diabetic foot infections.

Conclusion

       The microbiology of diabetic foot infections is diverse. Globally, S. aureus is the organism most commonly identified in diabetic foot infections, with MRSA representing 18.0% of S. aureus. There is a correlation between Gross National Income and diabetic foot microbiology, which likely reflects variations in sanitation. Knowledge of the microbiology of diabetic foot infections will help direct the development of novel therapeutics, such as bacteriophage therapy.

Abbreviations

       CIs: 95% Confidence intervals; MRSA: Methicillin-resistant Staphylococcus aureus; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

Supplementary Information

       The online version contains supplementary material available at https://doi. org/10.1186/s 12879-021-06516-7.

       Supplementary file 1: PRISMA checklist

       Supplementary file 2: Data extracted from included studies

       Supplementary file 3: Critical appraisal

Acknowledgements

Not applicable.

Authors’ contributions

      Conceived and designed the study: SB, JDJ. Analysed the data: KM, SB, HJS, JDJ. Wrote the manuscript: JDJ. Reviewed the manuscript: KM, SB, HJS, JDJ. All authors read and approved the final manuscript.

Funding

      This work was part of a University of Edinburgh/Medical Research Council Confidence in Concept Grant awarded to JDJ (MC_PC_18046). The funders had no role in the design of the study and collection, analysis, or interpretation of data nor in writing the manuscript.

Availability of data and materials

       Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Declarations

Ethics approval and consent to participate

       This article does not contain any studies with human participants or animals performed by any of the authors.

Consent for publication

       Not applicable.

Competing interests

       The authors declare that they have no competing interests.

Author details

       1 Infection Medicine, Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK. 2 Faculty of Medicine and Health Sciences, McGill University, 3605 Rue de la Montagne, Montreal, QC H3G 2M1, Canada. 3 Edinburgh Medical School, University of Edinburgh, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK.

Received: 17 June 2021 Accepted: 28 July 2021

Published online:09 August 2021

References

1. Kharroubi AT, Darwish HM. Diabetes mellitus: the epidemic of the century. World J Diab. 2015;6(6):850–67.

2. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293(2):217–28.

3. Insight Health Economics. Foot care in diabetes: the human and financial cost [Internet]. 2017 [cited 2021 Aug 7]. http://www.londonscn.nhs.uk/ wp-content/uploads/2017/04/dia-foot-care-mtg-kerr 27042017.pdf

4. Noor S, Zubair M, Ahmad J. Diabetic foot ulcer—a review on pathophysiology, classification and microbial etiology. Diabetes Metab Syndr Clin Res Rev. 2015;9(3):192–9.

5. Schaper NC, van Netten JJ, Apelqvist J, Bus SA, Hinchliffe RJ, Lipsky BA. Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). Diab Metab Res Rev. 2020;36(S1):3266.

6. Ndosi M, Wright-Hughes A, Brown S, Backhouse M, Lipsky BA, Bhogal M, et al. Prognosis of the infected diabetic foot ulcer: a 12-month prospective observational study. Diabet Med. 2018;35(1):78–88.

7. Shettigar S, Shenoy S, Sevitha S, Rao P. Microbiological profle of deep tissue and bone tissue in diabetic foot osteomyelitis. J Clin Diagn Res. 2018;12:8.

8. Kwon KT, Armstrong DG. Microbiology and antimicrobial therapy for diabetic foot infections. Infect Chemother. 2018;50(1):11–20.

9. Jneid J, Lavigne JP, La Scola B, Cassir N. The diabetic foot microbiota: a review. Hum Microbiome J. 2017;1(5–6):1–6.

10. Shanmugam P, Susan SL. The bacteriology of diabetic foot ulcers, with a special reference to multidrug resistant strains. J Clin Diagn Res JCDR. 2013;7(3):441–5.

11. Charles PGP, Uçkay I, Kressmann B, Emonet S, Lipsky BA. The role of anaerobes in diabetic foot infections. Anaerobe. 2015;1(34):8–13.

12. Stacey HJ, Clements CS, Welburn SC, Jones JD. The prevalence of methicillin-resistant Staphylococcus aureus among diabetic patients: a meta-analysis. Acta Diabetol. 2019;56:907.

13. Pereira SG, Moura J, Carvalho E, Empadinhas N. Microbiota of chronic diabetic wounds: ecology, impact, and potential for innovative treatment strategies. Front Microbiol. 2017;21:8.

14. Malone M, Bjarnsholt T, McBain AJ, James GA, Stoodley P, Leaper D, et al. The prevalence of biofilms in chronic wounds: a systematic review and meta-analysis of published data. J Wound Care. 2017;26(1):20–5.

15. Anvarinejad M, Pouladfar G, Japoni A, Abbasi P, Bolandparvaz S, Satiary Z, et al. Isolation and antibiotic susceptibility of the microorganisms isolated from diabetic foot infections in Nemazee Hospital, Southern Iran. J Pathog. 2015;15:328796.

16. Saltoglu N, Dalkiran A, Tasova Y, Tetiker T, Sert M, Bayram H, et al. Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. Clin Microbiol Infect. 2010;16(8):1252–7.

17. Lesens O, Vidal M, Beytout J, Laurichesse H, Desbiez F, Tauveron I, et al. Culture of per-wound bone specimens: a simplified approach for the medical management of diabetic foot osteomyelitis. Clin Microbiol Infect. 2011;17(2):285–91.

18. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283(15):2008–12.

19. The World Bank. World Bank Country and Lending Groups [Internet]. 2018 [cited 2021 Aug 7]. https://datahelpdesk.worldbank.org/knowledgebase/ articles/906519

20. The Joanna Briggs Institute. Critical appraisal tools - JBI [Internet]. [cited 2021 Aug 7]. https://jbi. global/critical-appraisal-tools

21. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

22. MedCalc. Comparison of proportions calculator [Internet]. [cited 2021 Jun 12]. https://www.medcalc.org/calc/comparison_of_proportions.php

23. Vardakas KZ, Horianopoulou M, Falagas ME. Factors associated with treatment failure in patients with diabetic foot infections: an analysis of data from randomized controlled trials. Diab Res Clin Pract. 2008;80(3):344–51.

24. Zenelaj B, Bouvet C, Uckay I, Lipsky BA. Do diabetic foot infections with methicillin-resistant staphylococcus aureus differ from those with other pathogens? Int J Low Extrem Wounds. 2014;13(4):263–72.

25. Hatipoglu M, Turhan V, Mutluoglu M, Uzun G, Karabacak E, Lipsky BA.The microbiologic profle of diabetic foot infections in Turkey: a 20-year systematic review: diabetic foot infections in Turkey. Eur J Clin Microbiol Infect Dis. 2014;33(6):871–8.

26. Cadena J, Thinwa J, Walter EA, Frei CR. Risk factors for the development of active methicillin-resistant Staphylococcus aureus (MRSA) infection in patients colonized with MRSA at hospital admission. Am J Infect Control. 2016;44(12):1617–21.

27. Lin J, Xu P, Peng Y, Lin D, Ou Q, Zhang T, et al. Prevalence and characteristics of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus nasal colonization among a community-based diabetes population in Foshan, China. J Diab Investig. 2017;8(3):383–91.

28. Ramakant P, Verma AK, Chand G, Mishra A, Agarwal G, Agarwal A, et al. Changing microbiological profile of pathogenic bacteria in diabetic foot infections: time for a rethink on which empirical therapy to choose? Diabetologia. 2011;54(1):58–64.

29. Smith K, Butcher J, MacKay WG, Williams C, Collier A, Bal AM, et al. One step closer to understanding the role of bacteria in diabetic foot ulcers: characterising the microbiome of ulcers. BMC Microbiol. 2016;16(1):54.

30. Malone M, Johani K, Hu H, Vickery K, Jensen SO, Gosbell IB, et al. Next generation DNA sequencing of tissues from infected diabetic foot ulcers. EBioMedicine. 2017;21:142–9.

31. Eleftheriadou I, Tentolouris N, Argiana V, Jude E, Boulton AJ. Methicillinresistant Staphylococcus aureus in diabetic foot infections. Drugs. 2010;70(14):1785–97.

32. Fish R, Kutter E, Wheat G, Blasdel B, Kutateladze M, Kuhl S. Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. J Wound Care. 2016;25(7):S27-33.

33. Mishra SC, Chhatbar KC, Kashikar A, Mehndiratta A. Diabetic foot. BMJ. 2017;359:j5064.

34. University of York, Centre for Reviews and Dissemination. PROSPERO. [Internet]. [cited 2021 Aug 7]. https://www.crd.york.ac.uk/prospero/.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is by wound world,excerpted from the Macdonald et al. BMC Infect Dis.